Page last updated: 2024-11-05

troglitazone and Coronary Restenosis

troglitazone has been researched along with Coronary Restenosis in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takagi, T1
Yamamuro, A1
Tamita, K1
Yamabe, K1
Katayama, M1
Morioka, S1
Akasaka, T1
Yoshida, K1

Trials

1 trial available for troglitazone and Coronary Restenosis

ArticleYear
Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus.
    The American journal of cardiology, 2002, Feb-01, Volume: 89, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Chromans; Coronary Angiography; Coronary Artery Disease; Coron

2002